Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Omori

P3.01-54 a Historical Comparison of Patients With Advanced NSCLC Harboring Uncommon EGFR Mutations Before and After the Approval of Afatinib in Japan

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

2P132 Dielectric Spectroscopy of Short Oligo DNA : DNA Concentration, Length and Sa Lt Concentration Dependence of the Dielectric Increment

Seibutsu Butsuri
2005English

Related publications

Afatinib in Locally Advanced/Metastatic NSCLC Harboring Common EGFR Mutations, After Chemotherapy: A Phase IV Study

Lung Cancer Management
2019English

P1.01-92 a Phase II Study of Afatinib Treatment for Elderly Patients With Previously Untreated Advanced NSCLC Harboring EGFR Mutations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-111 Efficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFR-TKI in Elderly Patients With NSCLC Harboring Sensitive EGFR Mutations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

Oncologist
Cancer ResearchMedicineOncology
2015English

P3.01-68 Early SBRT to the Primary Tumor May Overcome the Icotinib Resistance in Patients With Advanced NSCLC Harboring EGFR Mutations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-80 Retrospective Analysis of the Impact of EGFR T790M Mutation Detection by Re-Biopsy in Patients With NSCLC Harboring EGFR Mutations.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-99 Effect of Pembrolizumab on Patients Harboring Uncommon Epidermal Growth Factor Receptor Mutations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-85 Real-World Gefitinib 1st Line Treatment of Patients With Advanced NSCLC and EGFR Mutations - Serbian Single Center Experience

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

157P Second-Line Afatinib for Patients With Locally Advanced or Metastatic NSCLC Harbouring Common EGFR Mutations: A Phase IV Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy